{"entity":{"id":"ciprofloxacin","kind":"drug","name":"Ciprofloxacin","aka":[],"tldr":"Ciprofloxacin is an antibiotic. In the UK it is the fluoroquinolone licensed to prevent infection in adults whose white cell count is expected to fall very low after chemotherapy.","summary":"The Cipro label covers skin, bone and joint, intra-abdominal, urinary, respiratory and other infections, with boxed warnings about tendon, nerve and central nervous system effects. NICE CG151 offers adults with acute leukaemias, stem cell transplants or solid tumours in whom significant neutropenia is expected prophylaxis with a fluoroquinolone during the expected period of neutropenia only, and notes that \"In September 2024, only ciprofloxacin was licensed for prophylaxis of infections in neutropenic patients\", referring to MHRA January 2024 advice on fluoroquinolone restrictions. The Cipro NDA was approved on 22 October 1987.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Ciprofloxacin","links":[{"label":"US label (DailyMed): Cipro","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0"},{"label":"NICE CG151: Neutropenic sepsis, prevention and management in people with cancer, recommendations","url":"https://www.nice.org.uk/guidance/cg151/chapter/Recommendations"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["levofloxacin"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["febrile-neutropenia","neutropenia"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Cipro / Ciproxin","modality":"Fluoroquinolone antibacterial (oral, intravenous)","supportive":true,"mechanism":"A fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV.","approvals":[{"region":"US","year":1987,"indication":"Skin, bone and joint, intra-abdominal, urinary, respiratory and other bacterial infections listed on the label","note":"Year is the Cipro NDA 019537 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ciprofloxacin/","neighbours":{"drug":[{"id":"levofloxacin","kind":"drug","name":"Levofloxacin","route":"/drugs/levofloxacin/"}],"term":[{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"}]}}